SML0613

Rofecoxib

≥98% (HPLC)

• Synonim(y): 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
• Wzór empiryczny (zapis Hilla): C₁₇H₁₄O₄S
• Numer CAS: 162011-90-7
• Masa cząsteczkowa: 314.36
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: [S](=O)(=O)(C)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3
• InChI: 1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
• InChI key: RZJQGNCSTQAWON-UHFFFAOYSA-N

Opis

Application

Rofecoxib has been used in high performance bioaffinity chromatography.

Biochem/physiol Actions

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2.

Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.

Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS07
• Słowo ostrzegawcze: Warning
• Kody zagrożeń: H302
• Ostrzeżenia: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Klasa składowania: 11 - Combustible Solids
• Co się dzieje?: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable